Your browser doesn't support javascript.
loading
Adverse outcome pathways: From research to regulation scientific workshop report.
Kleinstreuer, Nicole C; Sullivan, Kristie; Allen, David; Edwards, Stephen; Mendrick, Donna L; Embry, Michelle; Matheson, Joanna; Rowlands, J Craig; Munn, Sharon; Maull, Elizabeth; Casey, Warren.
Affiliation
  • Kleinstreuer NC; National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA. Electronic address: Nicole.kleinstreuer@nih.gov.
  • Sullivan K; Physicians Committee for Responsible Medicine, Washington, DC, USA.
  • Allen D; Integrated Laboratory Systems, Inc., Research Triangle Park, NC, USA.
  • Edwards S; National Health and Environmental Effects Research Laboratory, U.S. Environmental Protection Agency, Research Triangle Park, NC, USA.
  • Mendrick DL; National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, USA.
  • Embry M; ILSI Health and Environmental Sciences Institute, Washington, DC, USA.
  • Matheson J; U.S. Consumer Product Safety Commission, Rockville, MD, USA.
  • Rowlands JC; The Dow Chemical Company, Midland, MI, USA.
  • Munn S; Joint Research Centre, European Commission, Ispra, Italy.
  • Maull E; National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA.
  • Casey W; National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA.
Regul Toxicol Pharmacol ; 76: 39-50, 2016 Apr.
Article in En | MEDLINE | ID: mdl-26774756
ABSTRACT
An adverse outcome pathway (AOP) helps to organize existing knowledge on chemical mode of action, starting with a molecular initiating event such as receptor binding, continuing through key events, and ending with an adverse outcome such as reproductive impairment. AOPs can help identify knowledge gaps where more research is needed to understand the underlying mechanisms, aid in chemical hazard characterization, and guide the development of new testing approaches that use fewer or no animals. A September 2014 workshop in Bethesda, Maryland considered how the AOP concept could improve regulatory assessments of chemical toxicity. Scientists from 21 countries, representing industry, academia, regulatory agencies, and special interest groups, attended the workshop, titled Adverse Outcome Pathways From Research to Regulation. Workshop plenary presentations were followed by breakout sessions that considered regulatory acceptance of AOPs and AOP-based tools, criteria for building confidence in an AOP for regulatory use, and requirements to build quantitative AOPs and AOP networks. Discussions during the closing session emphasized a need to increase transparent and inclusive collaboration, especially with disciplines outside of toxicology. Additionally, to increase impact, working groups should be established to systematically prioritize and develop AOPs. Multiple collaborative projects and follow-up activities resulted from the workshop.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Signal Transduction / Toxicity Tests / Drug-Related Side Effects and Adverse Reactions Type of study: Etiology_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Limits: Animals / Humans Language: En Journal: Regul Toxicol Pharmacol Year: 2016 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Signal Transduction / Toxicity Tests / Drug-Related Side Effects and Adverse Reactions Type of study: Etiology_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Limits: Animals / Humans Language: En Journal: Regul Toxicol Pharmacol Year: 2016 Document type: Article